Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.
23 people · 0 jobs
10 people · 0 jobs
11 people · 0 jobs
11 people · 0 jobs
8 people · 0 jobs
6 people · 0 jobs